Autolus Therapeutics
AUTL
110 hedge funds and large institutions have $395M invested in Autolus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 14 closing their positions.
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
9% more funds holding
Funds holding: 101 → 110 (+9)
10% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.84% less ownership
Funds ownership: 67.14% → 63.3% (-3.8%)
39% less capital invested
Capital invested by funds: $648M → $395M (-$253M)
77% less call options, than puts
Call options by funds: $84K | Put options by funds: $362K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10.8M |
| 2 |
AC
Armistice Capital
New York
|
+$7.87M |
| 3 |
Axa
Paris,
France
|
+$6.17M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.8M |
| 5 |
Millennium Management
New York
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.7M |
| 3 |
SC
Stempoint Capital
New York
|
-$9.5M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$8.23M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.24M |
AUTL Hedge Fund Activity: Q4 2024 in Review
110 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2024, worth a combined $395M — down 39% from $648M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AUTL positions and 14 closed out — a net gain of 9 holders — while 34 added to existing stakes and 31 trimmed.
The largest buyer was Candriam SCA, opening a new position worth an estimated $10.8M. The largest seller was Deerfield Management, exiting entirely with an estimated $13.2M sold.
- 110 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2024, up from 101 in Q3 2024.
- Funds reported $395M of Autolus Therapeutics stock for Q4 2024, down 39% quarter-over-quarter.
- 23 funds opened new Autolus Therapeutics positions in Q4 2024 and 14 closed out, a net change of +9 holders.
- The largest Autolus Therapeutics buyer in Q4 2024 was Candriam SCA, an estimated $10.8M added.
- The largest Autolus Therapeutics seller in Q4 2024 was Deerfield Management, an estimated $13.2M sold.
Based on aggregated 13F filings for Q4 2024.